A focus for Chinese trademark law and practice in recent years has been strengthening the fight against malicious trademarks. On 1 November 2019, the amended Trademark Law of the People’s Republic of China (the Trademark Law) was officially implemented, in which Article 4 primarily embodies China's determination to strengthen the fight against malicious trademarks and significantly lowers the threshold for fighting against them, while also serving as the latest weapon in the country’s crackdown...
Han Kun is a leading full-service law firm in China. Over the years, Han Kun has been widely recognized as a leader in complex cross-border and domestic transactions.
Our main practice areas include private equity, mergers and acquisitions, international and domestic capital markets, investment funds, asset management, antitrust/competition, banking and finance, aviation finance, foreign direct investment, compliance, private client/wealth management, intellectual property and dispute resolution.
We have more than 600 professionals located in our four offices in Beijing, Shanghai, Shenzhen and Hong Kong. All our lawyers are graduates of top universities and have extensive experience in complex cross-border transactions as counsel to both Chinese and foreign clients.
Year this Office was Established: 2004
Lawyers Worldwide: 622
Areas of Practice
On April 27, the Cyberspace Administration of China ("CAC") and 11 other departments jointly announced the promulgation of the Measures for Cybersecurity Review (the "Measures"), which will come into effect on June 1, 2020 and replace the current Measures for Security Review of Network Products and Services (for Trial Implementation) (the "Trial Measures"). The Measures aim to ensure the security of supply chains for critical information infrastructure (“CII”) and guarantee national security by prescribing a security review by the Cybersecurity Review Office (the "CRO") for certain network products and services purchased by CII operators...
Han Kun has advised Connect Biopharma Holdings Limited as its PRC legal advisor in connection with the company's U.S. initial public offering and listing on the Nasdaq Global Market under the symbol "CNTB." Founded in 2012, Connect Biopharma is dedicated to clinical stage research and development of novel immunomodulators for the treatment of severe autoimmune diseases and inflammation. Connect Biopharma has built a high-throughput drug screening platform based on T cell immune regulation function, based on its T cell immune regulation technology platform and the strength of expertise and experience in the field of immunology...
Five Han Kun-advised deals were recognized as "Deals of the Year 2019" by China Business Law Journal. These deals include the following: Aihuishou Acquires JD Paipai In June 2019, Aihuishou, a Chinese electronic product recycling platform, acquired JD Group's secondhand merchandise trading platform Paipai. JD also invested in Aihuishou more than US$500 million. Once the acquisition was completed, Aihuishou and JD agreed on a strategic co-operation. Douyu's Nasdaq IPO Douyu is a live barrage video platform that mainly broadcasts games. In July 2019, Douyu was listed on the Nasdaq Stock Exchange, raising about US$775 million...